Around 3.4 million people - six per cent of the population - had been infected with Covid-19 by July 13, according to the REACT-2 study published by Imperial College London today.
The study tracked the spread of infection across England following the first peak of the pandemic. Over 100,000 volunteers tested themselves at home using a finger prick test between June 20 and July 13 to check if they had antibodies against the virus.
People living in London were most likely to have been infected, as were those working in care homes and health care, and people from Black, Asian and other minority ethnic groups, along with people living in larger households.
Key findings in the study show that:
REACT-2 is the first mass antibody surveillance study to be rolled out across the country using a finger prick test that could be used by individuals at home if given approval in the future.
While the research showed several finger prick tests were accurate enough for large-scale surveillance studies to monitor the spread of Covid-19, no antibody fingerpick test has yet been approved by the MHRA for individual use.
The surveillance study will be repeated in autumn and will test a further 200,000 people for antibodies.
Testing positive for antibodies does not necessarily mean a person is immune to Covid-19. Currently, there is no firm evidence that the presence of antibodies means someone cannot be re-infected with the virus.
Professor Graham Cooke, NIHR Research Professor of Infectious Diseases and research lead at Imperial, said: “There are still many unknowns with this new virus, including the extent to which the presence of antibodies offers protection against future infections.”
If someone tests positive for antibodies, they still need to follow national guidelines including social distancing measures, getting a swab test if they have symptoms and wearing face coverings where required.
This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.
We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.